Catalysts · TAK · CIK 1395064 · page 2 of 2

TAK catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on TAK PDUFA dates and upcoming catalysts. This page continues the list.

Upcoming catalysts (continued)

DateDrugCompanyEventIndicationStatusSource
Aug to Nov 2028Quarter disclosedTAK-330TAKTopline readoutCoagulation DisorderScheduledClinicalTrials.gov
Aug to Nov 2028Quarter disclosedfazirsiran (TAK-999)TAKTopline readoutAlpha1-Antitrypsin DeficiencyScheduledClinicalTrials.gov
August 2028Month disclosedfazirsiran (TAK-999)TAKPrimary completionAlpha1-Antitrypsin DeficiencyScheduledClinicalTrials.gov
August 2028Month disclosedTAK-330TAKPrimary completionCoagulation DisorderScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedelritercept (KER-050)TAKTopline readoutMyelodysplastic SyndromesScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedmezagitamab (TAK-079)TAKTopline readoutKidney DiseaseScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedigi, 10% (TAK-339)TAKTopline readoutMultiple Myeloma; Secondary ImmunodeficiencyScheduledClinicalTrials.gov
September 2028Month disclosedmezagitamab (TAK-079)TAKPrimary completionKidney DiseaseScheduledClinicalTrials.gov
September 2028Month disclosedigi, 10% (TAK-339)TAKPrimary completionMultiple Myeloma; Secondary ImmunodeficiencyScheduledClinicalTrials.gov
September 2028Month disclosedelritercept (KER-050)TAKPrimary completionMyelodysplastic SyndromesScheduledClinicalTrials.gov
November 2028Month disclosedTAK-928TAKPrimary completionIO Resistant Squamous and Nonsquamous NSCLCScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedTAK-928TAKTopline readoutIO Resistant Squamous and Nonsquamous NSCLCScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosedfazirsiran (TAK-999)TAKTopline readoutAlpha1-Antitrypsin DeficiencyScheduledClinicalTrials.gov
January 2029Month disclosedidursulfase-itTAKPrimary completionHunter SyndromeScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosedidursulfase-itTAKTopline readoutHunter SyndromeScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosedmezagitamab (TAK-079)TAKTopline readoutAntibody-Mediated Rejection (AMR)ScheduledClinicalTrials.gov
January 2029Month disclosedmezagitamab (TAK-079)TAKPrimary completionAntibody-Mediated Rejection (AMR)ScheduledClinicalTrials.gov
January 2029Month disclosedfazirsiran (TAK-999)TAKPrimary completionAlpha1-Antitrypsin DeficiencyScheduledClinicalTrials.gov
Apr to Jul 2029Quarter disclosedelritercept (KER-050)TAKTopline readoutMyelodysplastic Syndrome; AnemiaScheduledClinicalTrials.gov
April 2029Month disclosedelritercept (KER-050)TAKPrimary completionMyelodysplastic Syndrome; AnemiaScheduledClinicalTrials.gov
Jul to Oct 2029Quarter disclosedmezagitamab (TAK-079)TAKTopline readoutImmune Thrombocytopenic Purpura (ITP)ScheduledClinicalTrials.gov
July 2029Month disclosedmezagitamab (TAK-079)TAKPrimary completionImmune Thrombocytopenic Purpura (ITP)ScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedTAK-279TAKTopline readoutPlaque PsoriasisScheduledClinicalTrials.gov
August 2029Month disclosedTAK-279TAKPrimary completionPlaque PsoriasisScheduledClinicalTrials.gov
Sep to Dec 2029Quarter disclosedTrintellix (vortioxetine hydrobromide)TAKTopline readoutMajor Depressive DisorderScheduledClinicalTrials.gov
September 2029Month disclosedTrintellix (vortioxetine hydrobromide)TAKPrimary completionMajor Depressive DisorderScheduledClinicalTrials.gov
Oct 2029 to Jan 2030Quarter disclosedelritercept (KER-050)TAKTopline readoutMyelodysplastic Syndromes; CytopeniaScheduledClinicalTrials.gov
October 2029Month disclosedelritercept (KER-050)TAKPrimary completionMyelodysplastic Syndromes; CytopeniaScheduledClinicalTrials.gov
Dec 2029 to Mar 2030Quarter disclosedzasocitinib (TAK-279)TAKTopline readoutCrohn's Disease; Ulcerative ColitisScheduledClinicalTrials.gov
Dec 2029 to Mar 2030Quarter disclosedzasocitinib (TAK-279)TAKTopline readoutPsoriatic ArthritisScheduledClinicalTrials.gov
Dec 2029 to Mar 2030Quarter disclosedelritercept (KER-050)TAKTopline readoutMyelofibrosis; AnemiaScheduledClinicalTrials.gov
December 2029Month disclosedelritercept (KER-050)TAKPrimary completionMyelofibrosis; AnemiaScheduledClinicalTrials.gov
December 2029Month disclosedzasocitinib (TAK-279)TAKPrimary completionPsoriatic ArthritisScheduledClinicalTrials.gov
December 2029Month disclosedzasocitinib (TAK-279)TAKPrimary completionCrohn's Disease; Ulcerative ColitisScheduledClinicalTrials.gov
Jan to Apr 2030Quarter disclosedEntyvio® (vedolizumab)TAKTopline readoutPouchitisScheduledClinicalTrials.gov
January 2030Month disclosedEntyvio® (vedolizumab)TAKPrimary completionPouchitisScheduledClinicalTrials.gov
Mar to Jun 2030Quarter disclosedvedolizumab iv (MLN0002)TAKTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Mar to Jun 2030Quarter disclosedtdv (TAK-003)TAKTopline readoutDengue FeverScheduledClinicalTrials.gov
March 2030Month disclosedtdv (TAK-003)TAKPrimary completionDengue FeverScheduledClinicalTrials.gov
March 2030Month disclosedvedolizumab iv (MLN0002)TAKPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Apr to Jul 2030Quarter disclosedvonicog alfa (TAK-577)TAKTopline readoutVon Willebrand Disease (VWD)ScheduledClinicalTrials.gov
Apr to Jul 2030Quarter disclosedzasocitinib (TAK-279)TAKTopline readoutPsoriatic ArthritisScheduledClinicalTrials.gov
April 2030Month disclosedvonicog alfa (TAK-577)TAKPrimary completionVon Willebrand Disease (VWD)ScheduledClinicalTrials.gov
April 2030Month disclosedzasocitinib (TAK-279)TAKPrimary completionPsoriatic ArthritisScheduledClinicalTrials.gov
Aug to Nov 2030Quarter disclosedvedolizumab sc (MLN0002)TAKTopline readoutUlcerative Colitis; Crohn's DiseaseScheduledClinicalTrials.gov
August 2030Month disclosedvedolizumab sc (MLN0002)TAKPrimary completionUlcerative Colitis; Crohn's DiseaseScheduledClinicalTrials.gov

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
December 9, 2025TAK-101TAKPrimary completionCeliac DiseaseCompletedClinicalTrials.gov
November 21, 2025Livtencity (maribavir)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
October 30, 2025TAK-771TAKPrimary completionPrimary Immunodeficiency Diseases (PID)CompletedClinicalTrials.gov
October 28, 2025TAK-771TAKPrimary completion—CompletedClinicalTrials.gov
October 17, 2025TAK-279TAKPrimary completionGeneralized Pustular Psoriasis; Erythrodermic PsoriasisCompletedClinicalTrials.gov
October 10, 2025Iclusig (ponatinib hydrochloride)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
September 24, 2025soticlestat (TAK-935)TAKPrimary completionDravet Syndrome (DS); Lennox Gastaut Syndrome (LGS)WithdrawnClinicalTrials.gov
Sep 2025Month disclosedSHP677TAKLabel expansion—ApprovedSEC Form 8-K
July 30, 2025soticlestat (TAK-935)TAKPrimary completionEpilepsy; Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS)WithdrawnClinicalTrials.gov
July 28, 2025TAK-341TAKPrimary completionMultiple System AtrophyCompletedClinicalTrials.gov
July 10, 2025Motegrity (prucalopride succinate)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
July 9, 2025tdv (TAK-003)TAKPrimary completionDengue FeverCompletedClinicalTrials.gov
July 1, 2025Entyvio® (vedolizumab)TAKPrimary completionColitis, UlcerativeCompletedClinicalTrials.gov
June 4, 2025TAK-861TAKPrimary completionNarcolepsy Type 1CompletedClinicalTrials.gov
June 3, 2025ORZEYFUL (oveporexton)TAKPrimary completionNarcolepsy Type 1CompletedClinicalTrials.gov
Jun 2025Month disclosedTAK-771TAKFDA approval—ApprovedSEC Form 8-K
May 30, 2025Entyvio® (vedolizumab)TAKPrimary completionUlcerative Colitis; Crohn's DiseaseCompletedClinicalTrials.gov
May 7, 2025darvadstrocel (CX601)TAKPrimary completionCrohn's Disease; Complex Perianal FistulaWithdrawnClinicalTrials.gov
May 5, 2025tdv (TAK-003)TAKPrimary completionHealthy VolunteersCompletedClinicalTrials.gov
March 18, 2025TAK-771TAKTopline readout—CompletedClinicalTrials.gov
March 3, 2025MIMRYLO™ (rusfertide)TAKTopline readoutPolycythemia Vera"PositiveSEC Form 8-K
April 18, 2024Entyvio® (vedolizumab)TAKFDA approvalmoderately to severely active Crohn's diseaseApprovedSEC 8-K Exhibit 99.1
March 19, 2024Iclusig (ponatinib hydrochloride)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
February 9, 2024Eohilia (budesonide)TAKFDA approval—ApprovedopenFDA Drugs@FDA
November 8, 2023FRUZAQLA® (fruquintinib)TAKFDA approvalTo treat refractory, metastatic colorectal cancerApprovedSEC 8-K Exhibit 99.1
September 27, 2023Entyvio® (vedolizumab)TAKFDA approval—ApprovedopenFDA Drugs@FDA
August 23, 2023Trintellix (vortioxetine hydrobromide)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
July 27, 2023Kazano (alogliptin benzoate; metformin hydrochloride)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
July 27, 2023Nesina (alogliptin benzoate)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
January 25, 2023Entyvio® (vedolizumab)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
April 28, 2022Ninlaro (ixazomib citrate)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
February 28, 2022ALUNBRIG (brigatinib)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
February 15, 2022Iclusig (ponatinib hydrochloride)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
December 17, 2021Eohilia (budesonide)TAKComplete Response Letter—CRL issuedFDA Complete Response Letters
November 23, 2021Livtencity (maribavir)TAKFDA approval—ApprovedopenFDA Drugs@FDA
September 15, 2021Exkivity (mobocertinib succinate)TAKFDA approval—ApprovedopenFDA Drugs@FDA
July 29, 2021Vyvanse (lisdexamfetamine dimesylate)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
January 22, 2021Trintellix (vortioxetine hydrobromide)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
December 18, 2020Iclusig (ponatinib hydrochloride)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
November 13, 2020Trintellix (vortioxetine hydrobromide)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
June 26, 2020Lialda (mesalamine)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
May 22, 2020ALUNBRIG (brigatinib)TAKLabel expansion—ApprovedopenFDA Drugs@FDA
December 17, 2019Entyvio® (vedolizumab)TAKComplete Response Letter—CRL issuedFDA Complete Response Letters
December 14, 2018Motegrity (prucalopride succinate)TAKFDA approval—ApprovedopenFDA Drugs@FDA
June 20, 2017Mydayis (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate)TAKFDA approval—ApprovedopenFDA Drugs@FDA
April 28, 2017ALUNBRIG (brigatinib)TAKFDA approval—ApprovedopenFDA Drugs@FDA
January 28, 2017Vyvanse (lisdexamfetamine dimesylate)TAKFDA approval—ApprovedopenFDA Drugs@FDA
January 26, 2016Dexilant Solutab (dexlansoprazole)TAKFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from TAK’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.